Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting. Bristol-Myers Squibb’s efforts to push the use of Opdivo earlier in the course of melanoma treatment have hit a snag ... surveillance, which is usual current management for completely resected

Latest news

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    The approval by the China National Drug Administration (CNDA) is for adults with unresectable or metastatic melanoma following failure of one prior line of therapy, and ends a drought in effective ... With the approval of pembrolizumab in China, the

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    melanoma, but Roche was unable to match that in a trial of its Zelboraf candidate. ... indicates that the drugs could "transform the standard of care in the melanoma adjuvant setting".

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older. ... led analysts at EvaluatePharma to predict that Merck

  • Opdivo tops Yervoy in adjuvant melanoma trial Opdivo tops Yervoy in adjuvant melanoma trial

    Top-line results from a phase III trial pitting Bristol-Myers Squibb's Opdivo against Yervoy reveal a clear win for troubled PD-1 inhibitor in adjuvant melanoma therapy. ... Opdivo (nivolumab) reduced the recurrence rate for patients with high-risk,

More from news
Approximately 2 fully matching, plus 68 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie ... While use of Imlygic has been limited,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics